Endocrine characteristics of polycystic ovary syndrome (PCOS)

Indian Journal of Experimental Biology

Volumn 41, Issue 7, 2003, Pages 694-700

  Szilagyi A ^a   Szabo I ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Anovulatory infertility; Endocrinopathy; PCOS; Polycystic ovary syndrome

Indexed keywords

BIOCHEMISTRY; INSULIN; PATHOLOGY; PATIENT MONITORING; SURGERY; ULTRASONIC APPLICATIONS;

INFERTILITY;

ENDOCRINOLOGY;

ALDOSTERONE ANTAGONIST; METFORMIN; ORAL CONTRACEPTIVE AGENT;

ENDOCRINE SYSTEM; FEMALE; HUMAN; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ALDOSTERONE ANTAGONISTS; CONTRACEPTIVES, ORAL, HORMONAL; ENDOCRINE SYSTEM; FEMALE; HUMANS; METFORMIN; POLYCYSTIC OVARY SYNDROME;

EID: 0037931461     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Adams J, Polson D W & Franks S, Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism, Br Med J, 293 (1986) 355.
2. Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R & Azziz R, Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: A prospective study, J Clin Endocrinol Metab, 83 (1998) 3078.
3. Diamanti-Kandaris E, Kouli C R, Bergiele A T, Filandra F A, Tsianateli T C, Spina G C, Zapanti E D & Bartzis M I, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile, J Clin Endocrinol Metab, 84 (1999) 4006.
4. Polson D W, Wadsworth J, Adams J, et al., Polycystic ovaries - A common finding in normal women, Lancet, 1 (1988) 870.
5. Michelmore K F, Balen A H, Dunger D B & Vessey M P, Polycystic ovaries and associated clinical and biochemical features in young women, Clin Endocrinol (Oxf.), 51 (1999) 779.
6. Adams J, Franks S, Polson D W, et al., Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone, Lancet, ii (1985) 1375.
7. Dunaif A, Insulin resistance and polycystic ovary syndrome: Mechanism and implications for pathogenesis, Endocrinol Rev, 18 (1997) 774.
8. Homburg R, What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome, Human Reprod, 17 (2002) 2495.
9. Dunaif A, Insulin resistance in polycystic ovary syndrome, Ann NY Acad Sci, 687 (1993) 60.
10. Ehrmann D A, Barnes R B & Rosenfield R L, Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion, Endocr Rev, 16 (1995) 322.
11. Homburg R, Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy, Human Reprod, 11 (1996) 29.
12. Szilágyi A & Rossmanith W G, Polyzystisches Ovar-Syndrom: Zentrale oder periphere Regulations-störung? Zent bl Gynakol, 113 (1991) 851.
13. Legro R S & Strauss J F, Molecular progress in infertility: Polycystic ovary syndrome, Fertil Steril, 78 (2002) 569.
14. Rosenfield R L, Barnes R B, Cara J F & Lucky A W, Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovary syndrome, Fertil Steril, 53 (1990) 785.
15. Franks S, Polycystic ovary syndrome: A changing perspective, Clin Endocrinol Oxf, 31 (1989) 87.
16. Yen S S C, The polycystic ovary syndrome, 12 (1980) 177.
17. Berga S L & Yen S S C, Opioid regulation of LH pulsatility in women with polycystic ovary syndrome, Clin Endocrinol, 30 (189) 177.
18. Szilágyi A, Hole R, Keckstein J, et al., Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease, Gynecol Endocrinol, 7 (1993) 159.
19. Barbieri R L, Makris A, Randall R W et al., Insulin stimulates androgen accumulation in incubation of ovarian stroma obtained from women with hyperandrogenism, J Clin Endocrinol Metab, 62 (1986) 904.
20. Homburg R, Pariente C, Lunenfeld B & Jacobs H S, The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome, Human Reprod, 7 (1992) 1379.
21. Cara J F, Fan J, Azzraello J & Rosenfield R L, Insulin-like growth factor-1 enhances luteinizing hormone binding capacity to rat ovarian theca-interstitial cells, J Clin Invest, 86 (1990) 560.
22. Poretsky L, Grigorescu F, Seibel M, Moses A C & Flier S, Distribution and characterization of insulin and insulin -like growth factor-1 receptors in normal human ovary, J Clin Endocrinol Metab, 61 (1985) 728.
23. Loughlin T, Cunningham S, Moore A, Culliton M, Smyth P P A & McKenna T J, Adrenal abnormalities in polycystic ovary syndrome, J Clin Endocrinol Metab, 62 (1986) 142.
24. Szilágyi A, Rossmanith W G, Csermely T, et al, Changes in circulating hormonal levels after ovarian wedge resection in patients with polycystic ovary syndrome, Arch Gynecol Obstet, 248 (1990) 31.
25. del Pozo E S & Falaschi P, Prolactin and cyclicity in polycystic ovary syndrome: Role of estrogens and the dopaminergic system, Prog Reprod Biol, 6 (1980) 252.
26. Barnes R B, Mileikowsky G N, Cha K Y, Spencer C A & Lobo R A: Effects of dopamine and metoclopramide in polycystic ovary syndrome, J Clin Endocrinol Metab, 63 (1986) 506.
27. Szilágyi A, Csermely T & Csaba I, Increased prolactin response to TRH in polycystic ovary syndrome with low basal prolactin values, Gynecol Endocrinol, 2 (1988) 313.
28. Steward P M, Shackleton C H L, Beastall G H, et al., 5α-reductase activity in polycystic ovary syndrome, Lancet, 335 (1990) 431.
29. Mauvais-Jarvis P, Regulation of androgen receptor and 5α-reductase in the skin of normal and hirsute women, Clin Endocrinol Metab, 15 (1986) 307.
30. Homoki J, Solyom J & Teller W M, Detection of late onset steroid 21-hydroxylase deficiency by capillary gas chromatographic profiling of urinary steroids in children and adolescents, Eur J Pediatr, 147 (1988) 257.
31. Seli E & Duleba A J, Should patients with polycystic ovarian syndrome be treated with metformin? Human Reprod, 17 (2002) 2230.
32. Leclair C & Patton P E, Advances in polycystic ovary syndrome treatment: Metformin and ovarian diathermy, Curr Womens Health Rep, 5 (2002) 333.
33. Kiesel L A, Rody A, Greb R R & Szilágyi A, Clinical use of GnRH analogues, Clin Endocrinol, 56 (2002) 677.
34. Chang R J, Laufer L R, Meldrum D R, et al., Steroid secretion in polycystic ovarian disease after ovarian suppression by a long acting gonadotropin-releasing hormone agonist, J Clin Endocrinol Metab, 56 (1983) 897.
35. Adashi E Y, Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism, Fertil. Steril, 53 (1990) 765.
36. Rittmaster R S, Use of gonadotropin-releasing hormone agonists in the treatment of hyperandrogenism, Clin Obstet Gynecol, 36 (1993) 679.
37. Luppa P, Muller B, Jacob K, et al., Variations of steroid hormone metabolism in serum and urine in polycystic ovary syndrome after nafarelin stimulation: Evidence for an altered corticoid excretion, J Clin Endocrinol Metab, 80 (1995) 280.
38. Shackleton C H L, Profiling steroid hormones and urinary steroids, J Chromatogr, 379 (1986) 91.
39. Homoki J, Solyom J, Wachter U, et al., Urinary excretion of 17-hydroxy-pregnanolones in patients with different forms of congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency, Eur J Pediatr, 151 (1992) 24.
40. Ferriman D & Gallwey J D, Clinical assessment of body hair growth in women, J Clin Endocrinol Metab, 11 (1961) 1440.
41. Steward P M, Shackleton C H L, Beastall G H, et al., 5α-reductase activity in polycystic ovary syndrome, Lancet, 335 (1990) 431.
42. Szilágyi A, Homoki J, Bellyei Sz & Szabó I, Hormonal and clinical effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome, Gynecol Endocrinol, 14 (2000) 337.
43. Shoham Z, Borenstein R, Lunenfeld B & Pariente C, Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles, Clin Endocrinol, 33 (1990) 271.
44. Stein I F & Cohen M R, Surgical treatment of bilateral ovaries, amenorrhea and sterility, Am J Obstet Gynecol, 38 (1939) 465.
45. Gjönnaess H, Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope, Fertil Steril, 41 (1984) 20.
46. Keckstein G, Rossmanith W G, Spatzier K, et al., The effect of laparoscopic treatment of polycystic ovarian disease by CO2-laser or Nd:YAG laser, Surg Endosc, 4 (1990) 103.
47. Rossmanith W G, Keckstein J, Spatzier K, et al., The impact of ovarian laser surgery on the gonadotropin secretion in women with polycystic ovarian disease, Clin Endocrinol, 34 (1991) 223.
48. Kovacs G, Buckler H, Bangah M, et al, Treatment of anovulation due to polycystic ovarian syndrome by laparoscopic ovarian electrocautery, Br J Obstet Gynecol, 98 (1991) 30
49. Kim L H, Taylor A E, Barbieri R L, Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility? Fertil Steril, 73 (2000) 1097.
50. Carr B R, Breslau N A, Givens C, et al, Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: A clinical research center study, J Clin Endocrinol Metab, 80 (1995) 1169.
51. Lemay A, Faure N, Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: A pilot study, J Clin Endocrinol Metab, 79 (1994) 1716.
52. Gjönnaess H, A simple treatment for polycystic ovarian syndrome, World Health Forum, 11 (1990) 214.